Novartis jumps into the KRAS race with a positive early snapshot — and a full slate of trials planned for ambitious bid to unseat Amgen
NEW ORLEANS — Amgen may have won the race to first approval among the KRAS G12C rivals, but that hasn’t deterred Novartis from unveiling an all-hands clinical campaign to get a best-of-class rival onto the market.
Novartis tipped its hand at AACR22, highlighting early data on JDQ443 that demonstrated a confirmed ORR of 57% — 4 of 7 patients — at the high, 200 mg dose for non-small cell lung cancer. That’s a solid debut for monotherapy results, but the investigators on the project are looking to do much better with a lineup of combination trials adding in a SHP2, in dose escalation since last June, along with their PD-1 inhibitor tislelizumab and a triplet using all 3.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.